Abstract

BRCA1 C-terminal domains are found in a specialized group of 23 proteins that function in the DNA damage response to protect genomic integrity. C-terminal domain phosphatase 1 (CTDP1) is the only phosphatase with a BRCA1 C-terminal domain in the human proteome, yet direct participation in the DNA damage response has not been reported. Examination of the CTDP1 BRCA1 C-terminal domain-specific protein interaction network revealed 103 high confidence interactions enriched in DNA damage response proteins, including FANCA and FANCI that are central to the Fanconi anemia DNA repair pathway necessary for the resolution of DNA interstrand crosslink damage. CTDP1 expression promotes DNA damage-induced FANCA and FANCD2 foci formation and enhances homologous recombination repair efficiency. CTDP1 was found to regulate multiple aspects of FANCI activity, including chromatin localization, interaction with γ-H2AX, and SQ motif phosphorylations. Knockdown of CTDP1 increases MCF-10A sensitivity to DNA interstrand crosslinks and double-strand breaks, but not ultraviolet radiation. In addition, CTDP1 knockdown impairs in vitro and in vivo growth of breast cancer cell lines. These results elucidate the molecular functions of CTDP1 in Fanconi anemia interstrand crosslink repair and identify this protein as a potential target for breast cancer therapy.

Details

Title
CTDP1 regulates breast cancer survival and DNA repair through BRCT-specific interactions with FANCI
Author
Wen-Feng, Hu 1 ; Krieger, Kimiko L 2   VIAFID ORCID Logo  ; Lagundžin, Dragana 3 ; Li, Xueli 4 ; Cheung, Ronald S 5 ; Taniguchi, Toshiyasu 6 ; Johnson, Keith R 2 ; Bessho, Tadayoshi 2 ; Monteiro, Alvaro N A 4   VIAFID ORCID Logo  ; Woods, Nicholas T 2 

 Eppley Institute for Research in Cancer and Allied Diseases, Fred & Pamela Buffett Cancer Center, University of Nebraska Medical Center, Omaha, NE, USA; Center for Molecular Medicine, Xiangya Hospital, Central South University, Changsha, China 
 Eppley Institute for Research in Cancer and Allied Diseases, Fred & Pamela Buffett Cancer Center, University of Nebraska Medical Center, Omaha, NE, USA 
 Eppley Institute for Research in Cancer and Allied Diseases, Fred & Pamela Buffett Cancer Center, University of Nebraska Medical Center, Omaha, NE, USA; Mass Spectrometry and Proteomics Core Facility, University of Nebraska Medical Center, Omaha, NE, USA 
 Department of Cancer Epidemiology, H. Lee Moffitt Cancer Center & Research Institute, Tampa, FL, USA 
 Divisions of Human Biology and Public Health Sciences, Fred Hutchinson Cancer Research Center, Seattle, WA, USA 
 Divisions of Human Biology and Public Health Sciences, Fred Hutchinson Cancer Research Center, Seattle, WA, USA; Department of Molecular Life Science, Tokai University School of Medicine, Isehara, Kanagawa, Japan 
Pages
1-17
Publication year
2019
Publication date
Jun 2019
Publisher
Springer Nature B.V.
e-ISSN
20587716
Source type
Scholarly Journal
Language of publication
English
ProQuest document ID
2243462713
Copyright
© 2019. This work is published under http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.